Safety of antithrombotic therapy in subjects with hereditary hemorrhagic telangiectasia: prospective data from a multidisciplinary working group

Subjects with the rare autosomal dominant disease Hereditary Hemorrhagic Telangiectasia (HHT) may develop medical conditions that require antithrombotic therapy (AT). However, safety of AT is uncertain in these patients and the only data currently available derive from retrospective analyses of regi...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Orphanet J Rare Dis
Главные авторы: Gaetani, Eleonora, Agostini, Fabiana, Porfidia, Angelo, Giarretta, Igor, Feliciani, Daniela, Di Martino, Luigi, Tortora, Annalisa, Gasbarrini, Antonio, Pola, Roberto
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2019
Предметы:
Letter to the Editor
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6933630/
https://ncbi.nlm.nih.gov/pubmed/31878955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-019-1278-z
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы